

PRESS RELEASE

IDOGEN AB



Corp. Reg. No. 556756-8521
Date: 30 March 2022

Idogen signs strategic collaboration agreement with contract research companies

Idogen AB (publ) has signed a strategic collaboration agreement with two contract research organizations (CRO), Klifo and 4Pharma, which will together with Idogen run the clinical phase 1/2a study with IDO 8, a new cell therapy for patients with severe hemophilia who have developed antibodies to their treatment with coagulation factor VIII. The collaboration agreement applies to all testing centers in Europe where the study will be conducted.

Idogen's tolerogenic cell therapy treatment IDO 8 aims to create tolerance for factor VIII and thus enable ongoing substitution treatment with coagulation factor VIII - a life-saving drug treatment for hemophilia A against which one third of patients develop antibodies. During the second quarter of 2022, a clinical phase 1/2a study will begin with IDO 8 where the goal is to evaluate safety and follow signals of treatment effect in patients.

The clinical phase 1/2a study with IDO 8 will be carried out at several European trial centers and in addition to Sweden, the company has so far submitted an application to be able to recruit patients in also in Norway. Klifo has been contracted for the overall responsibility for operationally conducting the clinical study, while 4Pharma's role is focused on the design of systems for the collection and processing of biometric study data.

"Last week, we received approval from the Medical Products Agency to start the IDO 8 study in Sweden, and with these collaboration agreements in place, we will soon be able to start patient recruitment. We look forward to welcoming the first patient into the study at the same time as we work in parallel to sign agreements with more trial centers in Europe," says Idogen's CEO Anders Karlsson.

The study will include nine patients and is expected to continue during 2022–2023. An initial follow-up will be done 26 weeks after treatment and a long-term follow-up will be done 52 weeks after completed treatment.

For further information, please contact:

Anders Karlsson, CEO, Idogen AB
Phone: +46 70 918 00 10
Email: anders.karlsson@idogen.com

Certified Adviser:

Erik Penser Bank AB, Box 7405, 103 91 Stockholm
Phone: +46 (0)8-463 80 00
Email: certifiedadviser@penser.se

The information was submitted for publication, through the agency of the contact persons set out above, on 30 March 2022 at 08:45 CET.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company's most advanced project,

PRESS RELEASE

IDOGEN AB



IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company's second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care. More information about Idogen is available via <https://www.idogen.com>